TEVA FINED $1.2BN AFTER PAY-FOR-DELAY

The FDA has fined the world’s largest generic drug maker Teva with $1.2 billion over allegations that it blocked the sale of cheaper medicines, pharmatimes.com reports. Israeli-based Teva has reached a settlement resolving the Commission’s antitrust suit charging its subsidiary Cephalon, with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil (modafinil). The settlement ...

PFIZER RUMOURED TO BID EUR 1.5BN FOR CELLECTIS

French biotech Cellectis is rumoured to be the next acquisition target for Pfizer as the US pharma major works out how to use its large overseas cash pile, pmlive.com reports. A report in the Financial Times, citing two people familiar with the situation – indicates that Pfizer has offered around EUR 1.5bn ($1.6bn) to take ...

OTSUKA LOSES LAWSUIT CHALLENGING FDA OVER ABILIFY

Otsuka has lost a lawsuit challenging the FDA’s decision to allow generic versions of the company’s antipsychotic drug Abilify, Reuters reports. At the end of April, the FDA approved applications to make Abilify by several generic drug makers, including Teva, which immediately announced it would launch its own version. Otsuka sued the FDA in March ...

AMARIN’S VASCEPA GRANTED EXCLUSIVITY IN US

A US district court has ruled that Amarin’s fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a FDA decision, Reuters reports. Amarin’s shares rose as much as 44 per cent to $2.80 on the Nasdaq. The stock was trading up 19 per cent at $2.33 on Thursday afternoon. Vascepa ...

FDA APPROVES IBS DRUGS FROM SALIX AND ACTAVIS

Two new treatments for IBS have been approved by the FDA, pharmatimes.com reports. Salix’ Xifaxan and Actavis’ Viberzi were given the green light to treat adults with IBS with diarrhoea (IBS-D). Julie Beitz, director of the FDA’s Office of Drug Evaluation III, said: “For some people, IBS can be quite disabling, and no one medication ...

NEW CANCER PILL FROM PFIZER APPROVED

The FDA has granted a new licence for Pfizer’s rare lung cancer drug Rapamune (sirolimus), the first time a treatment has gained approval for this form of the disease, pmlive.com reports. The US giant’s drug treats LAM a very rare, progressive lung disease that primarily affects women of childbearing age. This is the first drug ...

SYNERGY, STERIS DISPUTE FTC DECISION TO BLOCK DEAL

Sterilisation services provider Synergy Health and US medical tech company Steris said they would contest the FTC’s attempt to block Steris’s acquisition of the British company, Reuters reports. The companies said they were confident the court would reject the FTC’s request for an injunction blocking the merger. “We are very disappointed by the FTC’s decision ...

EXPRESS SCRIPTS IN FAVOUR OF PAY-PER-PERFORMANCE IN CANCER

Express Scripts has indicated it wants pharma companies selling certain cancer drugs to only be paid for their medicines if they provide a benefit to patients, pharmatimes.com reports. The pharmacy benefit manager (PBM) sees so-called pay-for-performance deals as the only way to fund the escalating cost of cancer care in the face of a stream ...

UK GOVERNMENT COMMITS TO INCREASE BUDGET OF NHS

The UK government will increase its healthcare spending in England by at least GBP 8 billion a year by 2020 and make the NHS a seven-day a week service, pharmatimes.com reports. The pledges formed the health focus of the Queen’s Speech, in which the newly-elected Conservative government set out its legislative agenda. Other plans will ...

NEW LICENCES FOR AUTOINFLAMMATORY DISORDERS RECOMMENDED BY NICE

After two months of not issuing guidance due to the UK’s General Election, NICE has today published a host of new recommendations for a number of drugs, pharmatimes.com reports. New draft guidance focuses heavily on recommending more options for treating ankylosing spondylitis, a type of inflammatory arthritis that affects the spine. NICE previously recommended AbbVie’s ...